A Vanderbilt Graduate and 2012 PharmaVoice 100 recipient with a 20 year history of leadership in theĀ development of landmark products including Tamiflu, Pegasys, Provenge and many others. Brad has a proven ability to connect with all levels of a clinical development program. Brad has led successful development programs with small, focused, single-compound companies as well as critical large-scale development programs with some of the largest pharmaceutical companies.